☰

Neel A. Shah, Ph.D. - Publications

Affiliations: 
2012 Pharmaceutical Systems and Policy West Virginia University, Morgantown, WV, United States 
Area:
Epidemiology, Pharmacy, Public Health
Tree Info Similar researchers PubMed Report error

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Averin A, Silvia A, Lamerato L, Richert-Boe K, Kaur M, Sundaresan D, Shah N, Hatfield M, Lawrence T, Lyman GH, Weycker D. Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 32880732 DOI: 10.1007/S00520-020-05715-3  0.308
2019 Richert-Boe K, Lamerato L, Lyman GH, Kaur M, Shah N, Lawrence T, Sundaresan D, Silvia A, Hanau A, Weycker D. Effectiveness of Prophylaxis with Granulocyte Colony-Stimulating Factor Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice Blood. 134: 4688-4688. DOI: 10.1182/Blood-2019-123559  0.311
2019 Lyman GH, Richert-Boe K, Lamerato L, Kaur M, Shah N, Lawrence T, Sundaresan D, Silvia A, Hanau A, Weycker D. Predictors of Febrile Neutropenia Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice Blood. 134: 5854-5854. DOI: 10.1182/Blood-2019-123524  0.308
2018 Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States. Headache. PMID 29446063 DOI: 10.1111/Head.13275  0.318
2017 Bonafede M, Cai Q, Cappell K, Kim G, Sapra SJ, Shah N, Widnell K, Winner P, Desai P. Factors Associated with Direct Health Care Costs Among Patients with Migraine. Journal of Managed Care & Specialty Pharmacy. 23: 1169-1176. PMID 29083975 DOI: 10.18553/Jmcp.2017.23.11.1169  0.309
2016 Gu T, Shah N, Deshpande G, Tang DH, Eisenberg DF. Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study. Drugs - Real World Outcomes. PMID 27757919 DOI: 10.1007/S40801-016-0093-2  0.346
2016 Gu T, Deshpande G, Tang D, Shah N, Harrison D, Eisenberg D, Stolshek B. one-year biologic cost per patient with psoriatic diseases in a managed care population : 3564 Journal of the American Academy of Dermatology. 74. DOI: 10.1016/J.Jaad.2016.02.1012  0.302
2015 Sauer BC, Teng CC, He T, Leng J, Lu CC, Walsh JA, Shah N, Harrison DJ, Tang DH, Cannon GW. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. Journal of Medical Economics. 1-34. PMID 26337538 DOI: 10.3111/13696998.2015.1086774  0.351
2015 Wu N, Bhurke S, Shah N, Harrison DJ. Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context. Clinicoeconomics and Outcomes Research : Ceor. 7: 257-66. PMID 25999750 DOI: 10.2147/Ceor.S83932  0.334
2015 Bonafede M, Johnson BH, Princic N, Shah N, Harrison DJ. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. Journal of Medical Economics. 18: 376-89. PMID 25530318 DOI: 10.3111/13696998.2014.1001849  0.332
2015 Bonafede MM, Johnson BH, Shah N, Tang DH, Stolshek BS, Harrison DJ. AB1109 A Retrospective Analysis on Predictors of Disease-Modifying Anti-Rheumatic Drug Initiation Among a Cohort of Patients with Newly Diagnosed Rheumatoid Arthritis Annals of the Rheumatic Diseases. 74: 1271-1272. DOI: 10.1136/Annrheumdis-2015-Eular.2094  0.344
2015 Gu T, Shah N, Deshpande G, Tang DH, Eisenberg DF, Stolshek BS, Harrison DJ. SAT0339 Comparative Effectiveness of First-Line Biologics Used for Rheumatoid Arthritis in a Managed Care Population Annals of the Rheumatic Diseases. 74: 781-782. DOI: 10.1136/Annrheumdis-2015-Eular.2083  0.343
2014 Howe A, Eyck LT, Dufour R, Shah N, Harrison DJ. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database. Journal of Managed Care & Specialty Pharmacy. 20: 1236-44. PMID 25443517 DOI: 10.18553/Jmcp.2014.20.12.1236  0.331
2014 Bonafede M, Joseph GJ, Shah N, Princic N, Harrison DJ. Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population. Clinicoeconomics and Outcomes Research : Ceor. 6: 381-8. PMID 25246804 DOI: 10.2147/Ceor.S61445  0.334
2014 Wu N, Lee YC, Shah N, Harrison DJ. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study. Clinical Therapeutics. 36: 1231-41, 1241.e1-3. PMID 25062652 DOI: 10.1016/J.Clinthera.2014.06.014  0.332
2014 Bonafede M, Johnson BH, Princic N, Shah N, Harrison DJ. SAT0076 Effectiveness of RA BIOLOGICS in the Two Years following Initiation Using A Validated Claims-Based Algorithm Annals of the Rheumatic Diseases. 73: 618-618. DOI: 10.1136/Annrheumdis-2014-Eular.2267  0.342
2014 Bonafede M, Johnson BH, Tang D, Shah N, Harrison D, Collier D. THU0441 Adherence and Persistence with Triple Non-Biologic Disease Modifying Antirheumatic Drug Therapy and Etanercept-Methotrexate Combination Therapy in US Patients with Rheumatoid Arthritis Annals of the Rheumatic Diseases. 73: 335-335. DOI: 10.1136/Annrheumdis-2014-Eular.1913  0.329
2014 Cannon GW, He T, Teng C-, Leng J, Lu C-, Tang D, Shah N, Harrison DJ, Sauer B. FRI0179 Comparative Effectiveness of Biologic Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis Annals of the Rheumatic Diseases. 73: 446-447. DOI: 10.1136/Annrheumdis-2014-Eular.1903  0.355
2014 Shah N, Bonafede MM, Chastek B, Thomson E, Song R, Harrison DJ. Treatment Persistence With Combination Versus Monotherapy In Commercially Insured Patients With Rheumatoid Arthritis Value in Health. 17. DOI: 10.1016/J.Jval.2014.03.296  0.344
2014 Bonafede MM, Johnson BH, Princic N, Shah N, Harrison DJ. Cost-Effectiveness Of Ra Biologics In The Two Years Following Initiation Using A Validated Claims-Based Algorithm In A United States Commercially Insured Population Value in Health. 17. DOI: 10.1016/J.Jval.2014.03.278  0.315
2013 Shah NA, Halverson J, Madhavan S. Burden of emergency and non-emergency colorectal cancer surgeries in West Virginia and the USA. Journal of Gastrointestinal Cancer. 44: 46-53. PMID 23143866 DOI: 10.1007/S12029-012-9455-5  0.483
2013 Bonafede M, Joseph GJ, Princic N, Shah NA, Harrison DJ. AB0767 Biologic treatment patterns in us managed care patients with employer provided health insurance treated for rheumatoid arthritis (ra) Annals of the Rheumatic Diseases. 72. DOI: 10.1136/Annrheumdis-2013-Eular.3089  0.36
2012 Shah N, Halverson J, Madhavan S. PSU36 Burden of Emergency and Non-Emergency Colorectal Cancer Resection Surgeries in West Virginia and the United States Value in Health. 15. DOI: 10.1016/J.Jval.2012.03.439  0.474
Show low-probability matches.